Search
Cartesian Therapeutics Inc
RNACAdd to Watchlist
6.280USD
+0.100+1.62%
Close 10-26 16:00（ET）
190.03MMarket Cap
LossP/E TTM
Cartesian Therapeutics Inc (RNAC) Stock Price Target & Forecast
Analyst Rating
Based on 7 analysts giving stock ratings to Cartesian Therapeutics Inc in the past month.
Buy
3 Strong Buy
4 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
33.667USD+436.95%
RNAC Analyst Recommendation Trends
In the current month, RNAC has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RNAC average Analyst price target in the last month is 33.667.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
3
3
3
3
3
3
3
3
4
4
5
5
5
5
4
4
0
0
0
0
0
1
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
7
8
8
8
9
9
9
RNAC Analyst Rating for Peer Comparison
Updated: Oct 20, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Insmed Inc
INSM
7
18
0
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
Biontech SE
BNTX
4
12
8
0
0
24
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
Cytokinetics Inc
CYTK
5
16
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Financial Forecasting
Based on analysts' estimates, RNAC EPS is projected to reach -0.940 in FY2026Q3, following reported EPS of 0.466 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.85
-0.88
-0.87
-0.94
-0.99
Actual
-3.56
-1.46
0.47
--
--
Surprise
-317.13%
-65.17%
+153.61%
--
--
FAQs
What is Cartesian Therapeutics Inc's expected revenue for the next quarter?
Cartesian Therapeutics Inc's expected revenue is 114.29K.
What is Cartesian Therapeutics Inc's price target?
Analysts forecast that Cartesian Therapeutics Inc's price target is USD 33.67, with the highest forecast at USD 44.00 and the lowest forecast at USD 16.00.
How have Cartesian Therapeutics IncRNAC's recent earnings per share performed?
The market expectation was USD 0.47, while Cartesian Therapeutics IncRNAC's earnings per share (EPS) for the previous quarter was USD -1.46. EPS for the next quarter is expected at USD -0.94.
What is the analyst rating for Cartesian Therapeutics Inc?
Based on the ratings of Cartesian Therapeutics Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.